임신과 정신약물 : 새로운 FDA 라벨 규칙과 약물치료의 이해

키워드

참고문헌 (75)

1. "Maternal mental health"[URL]
2. O'Hara MW, "Perinatal mental illness: definition, description and aetiology", Best Pract Res Clin Obstet Gynaecol, 28, pp.3~12 (2014)[DOI]
3. Kelly RH, "Adequacy of prenatal care among women with psychiatric diagnoses giving birth in California in 1994 and 1995", Psychiatr Serv, 50, pp.1584~1590 (1999)[DOI]
4. Bartel S, "Pregnancy Outcomes in Maternal Neuropsychiatric Illness and Substance Abuse", Geburtshilfe Frauenheilkd, 77, pp.1189~1199 (2017)[DOI]
5. Judd F, "Adverse obstetric and neonatal outcomes in women with severe mental illness: to what extent can they be prevented?", Schizophr Res, 157, pp.305~309 (2014)[DOI]
6. Einarson A, "Abrupt discontinuation of psychotropic drugs during pregnancy: fear of teratogenic risk and impact of counselling", J Psychiatry Neurosci, 26, pp.44~48 (2001)
7. Coverdale JH, "Respecting the autonomy of chronic mentally ill women in decisions about contraception", Hosp Community Psychiatry, 44, pp.671~674 (1993)
8. Nguyen TN, "Obstetric and neonatal outcomes of pregnant women with severe mental illness at a specialist antenatal clinic", Med J Aust, 199, pp.26~29 (2013)
9. Petersen I, "Risks and benefits of psychotropic medication in pregnancy: cohort studies based on UK electronic primary care health records", Health Technol Assess, 20, pp.1~176 (2016)
10. Hanley GE, "Patterns of psychotropic medicine use in pregnancy in the United States from 2006 to 2011 among women with private insurance", BMC Pregnancy Childbirth, 14, pp.242~ (2014)[DOI]
11. Andrade SE, "Use of antidepressant medications during pregnancy: a multisite study", Am J Obstet Gynecol, 198, pp.194 e1~194 e5 (2008)[DOI]
12. Addis A, "Risk classification systems for drug use during pregnancy: are they a reliable source of information?", Drug Saf, 23, pp.245~253 (2000)[DOI]
13. Law R, "FDA pregnancy risk categories and the CPS: do they help or are they a hindrance?", Can Fam Physician, 56, pp.239~241 (2010)
14. Brucker MC, "The 2015 US Food and Drug Administration Pregnancy and Lactation Labeling Rule", J Midwifery Womens Health, 62, pp.308~316 (2017)[DOI]
15. Wilmer E, "Drug safety: Pregnancy rating classifications and controversies", Clin Dermatol, 34, pp.401~409 (2016)[DOI]
16. Parker AJ, "Assessment of gestational age of the Asian fetus by the sonar measurement of crown-rump length and biparietal diameter", Br J Obstet Gynaecol, 89, pp.836~838 (1982)[DOI]
17. "Ginekol Pol", 1998, 682~692
18. Agarwal SS, "Neural tube defect: a preventable congenital malformation", Indian Pediatr, 36, pp.643~648 (1999)
19. Feghali M, "Pharmacokinetics of drugs in pregnancy", Semin Perinatol, 39, pp.512~519 (2015)[DOI]
20. Waldum HL, "Serum group I pepsinogens during pregnancy", Scand J Gastroenterol, 15, pp.61~63 (1980)[DOI]
21. Pirani BB, "Plasma volume in normal first pregnancy", J Obstet Gynaecol Br Commonw, 80, pp.884~887 (1973)[DOI]
22. Koh KH, "Kruppel-like factor 9 promotes hepatic cytochrome P450 2D6 expression during pregnancy in CYP2D6- humanized mice", Mol Pharmacol, 86, pp.727~735 (2014)[DOI]
23. Tracy TS, "Temporal changes in drug metabolism(CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy", Am J Obstet Gynecol, 192, pp.633~639 (2005)[DOI]
24. Myllynen P, "Developmental expression of drug metabolizing enzymes and transporter proteins in human placenta and fetal tissues", Expert Opin Drug Metab Toxicol, 5, pp.1483~1499 (2009)[DOI]
25. Tsutsumi K, "The effect of pregnancy on cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activities in humans", Clin Pharmacol Ther, 70, pp.121~125 (2001)[DOI]
26. Davison JM, "Renal hemodynamics and tubular function normal human pregnancy", Kidney Int, 18, pp.152~161 (1980)[DOI]
27. Anderson GD, "Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach", Clin Pharmacokinet, 44, pp.989~1008 (2005)[DOI]
28. Costantine MM, "Physiologic and pharmacokinetic changes in pregnancy", Front Pharmacol, 5, pp.65~ (2014)
29. Syme MR, "Drug transfer and metabolism by the human placenta", Clin Pharmacokinet, 43, pp.487~514 (2004)[DOI]
30. Prouillac C, "The role of the placenta in fetal exposure to xenobiotics: importance of membrane transporters and human models for transfer studies", Drug Metab Dispos, 38, pp.1623~1635 (2010)[DOI]
31. Gil S, "P-glycoprotein expression of the human placenta during pregnancy", Placenta, 26, pp.268~270 (2005)[DOI]
32. Weiss J, "Inhibition of P-glycoprotein by newer antidepressants", J Pharmacol Exp Ther, 305, pp.197~204 (2003)[DOI]
33. O'Brien FE, "Interactions between antidepressants and P-glycoprotein at the blood-brain barrier: clinical significance of in vitro and in vivo findings", Br J Pharmacol, 165, pp.289~312 (2012)[DOI]
34. Ewing G, "Placental transfer of antidepressant medications: implications for postnatal adaptation syndrome", Clin Pharmacokinet, 54, pp.359~370 (2015)[DOI]
35. Evans J, "Cohort study of depressed mood during pregnancy and after childbirth", BMJ, 323, pp.257~260 (2001)[DOI]
36. Wellings K, "The prevalence of unplanned pregnancy and associated factors in Britain: findings from the third National Survey of Sexual Attitudes and Lifestyles (Natsal-3)", Lancet, 382, pp.1807~1816 (2013)[DOI]
37. Miller LJ, "Sexuality, reproduction, and family planning in women with schizophrenia", Schizophr Bull, 23, pp.623~635 (1997)[DOI]
38. Pacek LR, "The bidirectional relationships between alcohol, cannabis, co-occurring alcohol and cannabis use disorders with major depressive disorder: results from a national sample", J Affect Disord, 148, pp.188~195 (2013)[DOI]
39. Regier DA, "Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area(ECA) Study", JAMA, 264, pp.2511~2518 (1990)[DOI]
40. Conway KP, "Co-occurrence of tobacco product use, substance use, and mental health problems among adults: Findings from Wave 1(2013-2014) of the Population Assessment of Tobacco and Health(PATH) Study", Drug Alcohol Depend, 177, pp.104~111 (2017)[DOI]
41. Kataoka MC, "Smoking during pregnancy and harm reduction in birth weight: a cross-sectional study", BMC Pregnancy Childbirth, 18, pp.67~ (2018)[DOI]
42. "Srp Arh Celok Lek", 1997, 267~271
43. Norgaard HC, "Overweight and obesity in patients with severe mental illness", Ugeskr Laeger, 178 (2016)
44. Holt RI, "Obesity, serious mental illness and antipsychotic drugs", Diabetes Obes Metab, 11, pp.665~679 (2009)[DOI]
45. Mandal D, "Maternal obesity and pregnancy outcome: a prospective analysis", J Assoc Physicians India, 59, pp.486~489 (2011)
46. Ovesen P, "Effect of prepregnancy maternal overweight and obesity on pregnancy outcome", Obstet Gynecol, 118, pp.305~312 (2011)[DOI]
47. Downs DS, "Obesity in Special Populations: Pregnancy", Prim Care, 43, pp.109~120 (2016)[DOI]
48. Stang J, "Position of the Academy of Nutrition and Dietetics: Obesity, Reproduction, and Pregnancy Outcomes", J Acad Nutr Diet, 116, pp.677~691 (2016)[DOI]
49. McIntyre RS, "Managing weight gain in patients with severe mental illness", J Clin Psychiatry, 70, pp.e23~ (2009)[DOI]
50. "Last updated Center for Disease Control and Prevention. Folic acid"[URL]
51. Wilson RD, "Pre-conception Folic Acid and Multivitamin Supplementation for the Primary and Secondary Prevention of Neural Tube Defects and Other Folic Acid-Sensitive Congenital Anomalies", J Obstet Gynaecol Can, 37, pp.534~552 (2015)[DOI]
52. Chisolm MS, "Management of psychotropic drugs during pregnancy", BMJ, 532, pp.h5918~ (2016)
53. Payne JL, "Antidepressant use during pregnancy: current controversies and treatment strategies", Clin Obstet Gynecol, 52, pp.469~482 (2009)[DOI]
54. Cohen LS, "Establishment of the National Pregnancy Registry for Atypical Antipsychotics", J Clin Psychiatry, 76, pp.986~989 (2015)
55. Cohen LS, "Reproductive Safety of Second-Generation Antipsychotics: Current Data From the Massachusetts General Hospital National Pregnancy Registry for Atypical Antipsychotics", Am J Psychiatry, 173, pp.263~270 (2016)[DOI]
56. Huybrechts KF, "Antipsychotic Use in Pregnancy and the Risk for Congenital Malformations", JAMA Psychiatry, 73, pp.938~946 (2016)[DOI]
57. Petersen I, "Risks associated with antipsychotic treatment in pregnancy: Comparative cohort studies based on electronic health records", Schizophr Res, 176, pp.349~356 (2016)[DOI]
58. Barnes TR, "Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology", J Psychopharmacol, 25, pp.567~620 (2011)[DOI]
59. Seeman MV, "Clinical interventions for women with schizophrenia: pregnancy", Acta Psychiatr Scand, 127, pp.12~22 (2013)[DOI]
60. Gentile S, "Antipsychotic therapy during early and late pregnancy. A systematic review", Schizophr Bull, 36, pp.518~544 (2010)[DOI]
61. Habermann F, "Atypical antipsychotic drugs and pregnancy outcome: a prospective, cohort study", J Clin Psychopharmacol, 33, pp.453~462 (2013)[DOI]
62. Huybrechts KF, "Antidepressant use late in pregnancy and risk of persistent pulmonary hypertension of the newborn", JAMA, 313, pp.2142~2151 (2015)[DOI]
63. Chambers CD, "Selective serotoninreuptake inhibitors and risk of persistent pulmonary hypertension of the newborn", N Engl J Med, 354, pp.579~587 (2006)[DOI]
64. Yonkers KA, "Antidepressant use in pregnant and postpartum women", Annu Rev Clin Psychol, 10, pp.369~392 (2014)[DOI]
65. Byatt N, "Antidepressant use in pregnancy: a critical review focused on risks and controversies", Acta Psychiatr Scand, 127, pp.94~114 (2013)[DOI]
66. Moses-Kolko EL, "Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications", JAMA, 293, pp.2372~2383 (2005)[DOI]
67. Koren G, "Diagnosis and management of poor neonatal adaptation syndrome in newborns exposed in utero to selective seretonin", norepinephrine reuptake inhibitors, 2009, pp.31, 348~350
68. Cohen LS, "A reevaluation of risk of in utero exposure to lithium", JAMA, 271, pp.146~150 (1994)[DOI]
69. Pearlstein T, "Use of psychotropic medication during pregnancy and the postpartum period", Womens Health (Lond), 9, pp.605~615 (2013)[DOI]
70. Christensen J, "Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism", JAMA, 309, pp.1696~1703 (2013)[DOI]
71. Bromley RL, "The prevalence of neurodevelopmental disorders in children prenatally exposed to antiepileptic drugs", J Neurol Neurosurg Psychiatry, 84, pp.637~643 (2013)[DOI]
72. Clark CT, "Lamotrigine dosing for pregnant patients with bipolar disorder", Am J Psychiatry, 170, pp.1240~1247 (2013)[DOI]
73. Dolk H, "Does lamotrigine use in pregnancy increase orofacial cleft risk relative to other malformations?", Neurology, 71, pp.714~722 (2008)[DOI]
74. Iqbal MM, "Effects of commonly used benzodiazepines on the fetus, the neonate, and the nursing infant", Psychiatr Serv, 53, pp.39~49 (2002)[DOI]
75. Lin AE, "Clonazepam use in pregnancy and the risk of malformations", Birth Defects Res A Clin Mol Teratol, 70, pp.534~536 (2004)[DOI]

관련 논문AI추천